OUR PEOPLE LEADERSHIP
Natalie Mount,
Chief Executive Officer,
Board Director
Natalie Mount
Chief Executive Officer,
Board Director
Dr. Natalie Mount MA, PhD, is the Chief Executive Officer and a Board Director at Cytospire Therapeutics. Natalie was previously CEO of Adaptate Biotherapeutics from inception until its successful acquisition by Takeda Pharmaceuticals in 2022. Adaptate specialized in the discovery and development of novel engagers. Prior to Adaptate, Natalie was Chief Scientific Officer of GammaDelta Therapeutics (also acquired by Takeda), building an allogeneic cell therapy platform for Immuno Oncology. Prior to GammaDelta, she was part of the founding management and the Chief Clinical Officer at the Cell and Gene Therapy Catapult. Natalie began her career at Pfizer, where she spent 16 years leading development activities, including Pfizer’s late pre-clinical and clinical portfolio of cell therapies.
Natalie has previously served on the Boards of several cell and gene therapy companies, including GenSight and Rinri Therapeutics and is currently an Independent Director at Wugen. She is a Venture Partner with the specialist life science venture investment firm Abingworth and serves on the Translational Advisory Board at the Crick Institute in London.
Natalie holds a first-class degree in Natural Sciences from the University of Cambridge and a Ph.D. in Biochemistry and Molecular Biology from University College, London.
Mark Uden,
Chief Technology Officer
Mark Uden
Chief Technology Officer
Dr. Mark Uden, PhD, is the Chief Technology Officer (CTO) at Cytospire Therapeutics. Mark was previously CTO of Adaptate Biotherapeutics until acquisition by Takeda. Preceding this he was V.P. Pharmaceutical Sciences at GammaDelta Therapeutics – also successfully acquired. Prior to this, Mark was a Senior Director, Product Development at GSK where he spent 17 years progressing GSK’s portfolio of early-stage Biopharmaceuticals from Discovery through CMC to the clinic. Mark also spent 4-years at Oxford Biomedica during its spin-out from Oxford University where he co-developed novel Lentiviral technologies and multiple Gene Therapy assets. Mark holds a Ph.D. in Biochemistry from Imperial College, London.
Andrew Fadden,
Chief Business Officer
Andrew Fadden
Chief Business Officer
Dr. Andrew Fadden, PhD, MBA, is the Chief Business Officer (CBO) at Cytospire Therapeutics. Andrew was previously CBO at Enara Bio, where he led the company’s corporate development function, helping to raise >$65m in equity capital and securing partnerships with major pharmaceutical companies.
Prior to this, Andrew was a Development Program Leader at Immunocore, where he led multiple early-phase programs from discovery research into clinical development. He was also a key part of the team that agreed a clinical-stage, co-development partnership with Genentech. Prior to Immunocore, Andrew was the Global Regulatory Affairs Lead for the Oncology Portfolio at Vertex Pharmaceuticals, and held positions of increasing responsibility in Global Regulatory Affairs and Global Development Teams at UCB and GlaxoSmithKline.
Andrew holds an M.Biochem degree in Molecular and Cellular Biochemistry from the University of Oxford and a PhD in Biochemistry from University College London following research at Cancer Research UK’s London Research Institute. Andrew also holds an Executive MBA (with Distinction) from Warwick Business School.
Robert Good,
Head of Biology
Rob Good
Head of Biology
Dr Rob Good, PhD, is the Head of Biology at Cytospire Therapeutics. Rob has over 10 years’ experience in biotech and big pharma in the fields of Oncology, Immunology and Respiratory drug discovery. In his previous role, Rob was a program lead at Takeda Pharmaceuticals, responsible for leading immune cell engager programs from early discovery through preclinical development towards IND. Prior to Takeda, Rob joined Adaptate Biotherapeutics as one of the founding members of the R&D team and lead a number of novel immune cell engager programs from early discovery to candidate selection before the successful acquisition of Adaptate by Takeda in 2022. Prior to Adaptate, Rob also held other scientific roles at GSK, Novartis and University College London as a postdoc in the Translational Research Office.
Rob holds a Bachelor of Science in Pharmacology from the University of Bath, and a Ph.D in Cell and Molecular Biology from University College, London.
James Legg,
Chief Scientific Officer
James Legg
Chief Scientific Officer
Dr. James Legg Ph.D is the Chief Scientific Officer at Cytospire Therapeutics. James was previously SVP Research and Early Development at Mestag Therapeutics, joining soon after its inception and helping to build its portfolio of biologics targeting specialised fibroblast populations in oncology and stromal checkpoint agonism in inflammatory and autoimmune disease. Prior to Mestag, James was SVP Research and Development at Crescendo Biologics, responsible for Crescendo’s Immuno Oncology Portfolio from research through to preclinical development including initiation and delivery of CB307, a CD137 x PSMA Humabody® into preclinical development as well as leading the biology/pharmacology functions.
James started his career at Cambridge Antibody Technology/AstraZeneca/MedImmune and has also consulted for a number of early stage biotechnology companies.
James holds a first class degree in Applied Biology from Bath University, a Ph.D in Molecular Cell Biology from Imperial College, London and undertook PostDoctoral research at Imperial Cancer Research Fund (Now CRUK) in London.
OUR PEOPLE BOARD OF DIRECTORS
Peter Goodfellow,
Chair of Board of Directors
Peter Goodfellow
Chair of Board of Directors
Peter was formerly Senior Vice President for Discovery Research at GlaxoSmithKline. Most recently he Chaired the Boards of GammaDelta Therapeutics and Adaptate Biotherapeutics. He has also held the Balfour chair in genetics at Cambridge University and research positions at the Imperial Cancer Research Fund. Peter holds doctorates from Oxford and Bristol Universities and is a Fellow of EMBO, the Academy of Medical Sciences and the Royal Society.
Bali Muralidhar
Non-Executive Director, Abingworth
Bali Muralidhar
Non-Executive Director, Abingworth
Bali Muralidhar is Managing Partner, Chief Investment Officer and COO of Abingworth, a transatlantic Life Sciences venture firm, based in London. Bali has over 15 years professional experience in healthcare across a range of functions including venture investing, R&D, clinical practice and teaching. He represents Abingworth on a number of portfolio company boards, both public and private and has been a member of the BVCA Venture Capital Committee since 2021. Prior to joining Abingworth, Bali was a senior partner at MVM Partners LLP in London and in 2018, was named among Financial News’ Rising Stars in Private Equity, which celebrated 25 men and women under the age of 40 standing out in the European private equity industry. Before MVM, Bali was a member of Bain Capital’s healthcare deal team. Bali obtained a degree in clinical medicine from the University of Oxford and practiced general surgery at the John Radcliffe and Addenbrooke’s Hospitals in Oxford and Cambridge, respectively. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge, and has published over a dozen peer reviewed papers. He was also a Bye-Fellow in Medical Sciences at Downing College, Cambridge where he taught pathology, surgery and medicine.
Owen Smith
Non-Executive Director, 4BIO Capital
Owen Smith
Non-Executive Director, 4BIO Capital
Owen is a Partner at 4BIO Capital, an international venture capital firm investing in advanced therapies and other emerging technologies to unlock the treatments of the future.
Since joining 4BIO Capital in 2018, Owen has been instrumental in supporting the fund in seeding companies as well as finding and growing potentially transformative innovations. Owen began his investment career at life science venture capital firms Arthurian Life Sciences and Arix Bioscience plc, giving him significant experience working with early-stage biotechnology companies. Owen holds an MSc in Experimental and Translational Therapeutics from the University of Oxford and is also qualified as an accountant, having spent several years working in assurance and advisory roles at Grant Thornton with public and private clients.
Owen is currently a Board Director at 4BIO portfolio companies SparingVision and Entact Bio, and is actively involved in several other investments. He previously acted as an Observer on the boards of LogicBio and Depixus while at Arix.
Natalie Mount,
Chief Executive Officer,
Board Director
Natalie Mount
Chief Executive Officer,
Board Director
Dr. Natalie Mount MA, PhD, is the Chief Executive Officer and a Board Director at Cytospire Therapeutics. Natalie was previously CEO of Adaptate Biotherapeutics from inception until its successful acquisition by Takeda Pharmaceuticals in 2022. Adaptate specialized in the discovery and development of novel engagers. Prior to Adaptate, Natalie was Chief Scientific Officer of GammaDelta Therapeutics (also acquired by Takeda), building an allogeneic cell therapy platform for Immuno Oncology. Prior to GammaDelta, she was part of the founding management and the Chief Clinical Officer at the Cell and Gene Therapy Catapult. Natalie began her career at Pfizer, where she spent 16 years leading development activities, including Pfizer’s late pre-clinical and clinical portfolio of cell therapies.
Natalie has previously served on the Boards of several cell and gene therapy companies, including GenSight and Rinri Therapeutics and is currently an Independent Director at Wugen. She is a Venture Partner with the specialist life science venture investment firm Abingworth and serves on the Translational Advisory Board at the Crick Institute in London.
Natalie holds a first-class degree in Natural Sciences from the University of Cambridge and a Ph.D. in Biochemistry and Molecular Biology from University College, London.
BOARD OBSERVERS
Jonathan Nash
Jonathan Nash
Jonathan joined LifeArc as an Investment Principal at LifeArc Ventures in 2024. He is responsible for new investments and managing existing portfolio companies.
Prior to joining LifeArc, Jon was an Associate with the Biotechnology team at M Ventures, the corporate venture arm of Merck KGaA, where he was responsible for new investments and existing portfolio companies with a focus on therapeutics and life sciences. Prior to this, he was an Associate at UBS in the Healthcare Investment Banking Group in London, as well as a Life Science Specialist at L.E.K. Consulting.
Jon started his career as a doctor in London and holds Degrees in Medicine and Neuroscience from Imperial College London.
Lucille Conroy
Lucille Conroy
Lucille is a Principal at Abingworth with more than 11 years of experience in the healthcare industry, spanning venture investing, strategy consulting, clinical practice, and academic research. Previously, Lucille was an investor at F-Prime Capital where she was involved in a funding and formation of several companies, including Arvelle Therapeutics (acquired by Angelini for $960M). Before F-Prime, Lucille was a consultant with McKinsey & Company. Lucille served as a physician for a number of years at The National Hospital for Neurology and Neurosurgery, Imperial College and Barts Healthcare trusts. Lucille holds degrees in Clinical Neuroscience and in Medicine with distinction from the University of Glasgow. She is a Member of the Royal College of Physicians in London.
Natalie Johnston
Natalie Johnston
Natalie Johnston, PhD, Principal at 4BIO Capital
Natalie joined the 4BIO Capital as an Analyst in 2019. She works in the investment team sourcing and accessing deals alongside acting as a Board Observer for Ray Therapeutics and ViaNautis. Before joining the firm, she worked within financial services at Gerson Lehrman Group providing diligence assistance to investment banks, hedge funds and venture capital firms operating in the healthcare sector. Natalie holds PhD from Imperial College London, and a BSc in Biochemistry from the University of Glasgow.
INVESTORS
